CR Group L.P. 4
4 · T2 Biosystems, Inc. · Filed Feb 16, 2024
Insider Transaction Report
Form 4
Capital Royalty L.P.
10% Owner
Transactions
- Conversion
Series B Preferred Stock
2024-02-14−33,594.71→ 0 total(indirect: By: CRG Partners III (Cayman) Lev AIV I L.P.)From: 2023-07-03→ Common Stock (335,947 underlying) - Conversion
Common Stock
2024-02-14+335,947→ 335,947 total(indirect: By CRG Partners III (Cayman) Lev AIV I L.P.) - Conversion
Common Stock
2024-02-14+488,273→ 488,273 total(indirect: By: CRG Partners III Parallel Fund B LP) - Conversion
Series B Preferred Stock
2024-02-14−48,827.3→ 10,875.25 total(indirect: By: CRG Partners III Parallel Fund B LP)From: 2023-07-03→ Common Stock (488,273 underlying)
Footnotes (3)
- [F1]Each share of Series B Preferred Stock converted into 10 shares of Common Stock for no additional consideration.
- [F2]CR Group L.P. may be deemed to beneficially own these shares by virtue of its position as the investment manager for the CRG Entities.
- [F3]The preferred stock has no expiration date.